Analysts’ Viewpoint
Increase in prevalence of cardiovascular diseases, surge in geriatric population, and rise in availability of combination therapies are driving the global calcium channel blockers market. Development of newer formulations and increase in healthcare expenditure are expected to bolster market growth. Furthermore, rise in awareness among healthcare professionals and patients about the benefits of calcium channel blockers (CCBs) are propelling global calcium channel blockers market size.
Increase in adoption of combination therapies and development of newer formulations of CCBs with improved pharmacokinetic properties and fewer side effects offer lucrative opportunities to market players. Companies are focusing on development of customized CCBs that can be tailored to individual patients' needs. Rise of telemedicine and remote patient monitoring is expected to increase access to CCBs and improve patient outcomes.
However, availability of alternative treatment options, such as ACE inhibitors and beta-blockers, is likely to hamper market growth in the next few years.
Calcium channel blockers (CCBs) are a class of drugs used to treat various medical conditions, particularly cardiovascular diseases such as hypertension (high blood pressure) and angina (chest pain). These drugs work by blocking the entry of calcium ions into the smooth muscle cells of blood vessels, which causes the vessels to relax and dilate. This reduces blood pressure and improves blood flow, which can help to prevent heart attacks, strokes, and other serious medical events.
Calcium channels are protein pores that allow the entry of calcium ions into cells. In the cardiovascular system, calcium channels are located in the smooth muscle cells that surround blood vessels and in the heart muscle cells. When calcium ions enter these cells, they trigger muscle contraction, which could lead to increased blood pressure and reduced blood flow.
CCBs work by selectively blocking the entry of calcium ions into the smooth muscle cells of blood vessels, which causes the vessels to relax and dilate. This reduces blood pressure and improves blood flow, which can help to prevent heart attack, stroke, and other serious medical events. CCBs also have other effects on the cardiovascular system, such as reducing heart rate and improving the oxygen supply to the heart.
Rise in prevalence of cardiovascular diseases and increase in demand for safe and effective treatment options are projected to bolster global calcium channel blockers market demand. However, emergence of alternative treatment options and increase in availability of generic drugs are likely to hamper market growth in the near future.
Cardiovascular diseases (CVDs) and hypertension are among the leading causes of mortality across the world, accounting for an estimated 17.9 million deaths per year, according to the World Health Organization.
Incidence of these diseases is expected to rise, as the global population ages and lifestyle factors such as poor diet, sedentary lifestyles, and stress increase. Surge in incidence of CVDs and hypertension is a major driver of the global calcium channel blockers market development.
According to the World Health Organization, hypertension affects about 1.13 billion people globally, and the number is expected to increase to 1.56 billion by 2025. Hypertension is a major risk factor for heart disease, stroke, and other complications, and calcium channel blockers drugs are among the most commonly prescribed medications for hypertension.
According to the American Heart Association, nearly 108 million adults in the U.S. have hypertension, which is approximately 45% of the population. Hypertension is also a leading cause of heart attacks, strokes, and heart failure. Similarly, the European Society of Cardiology estimates that CVDs account for 45% of all deaths in Europe, with hypertension being a major risk factor for CVDs.
The situation is similar in emerging economies such as India and China, where the incidence of hypertension and CVDs is rising rapidly. According to a report by the Indian Council of Medical Research, the prevalence of hypertension in India has increased from 20% in 2010 to 25% in 2020, affecting approximately 260 million people.
The Chinese Hypertension Control Alliance estimates that over 300 million people in China suffer from hypertension. Consequently, demand for CCB drugs is increasing in these countries, which is driving the calcium channel blockers industry in the country.
The shift toward combination therapies is one of the primary factors driving the global calcium channel blockers market value. Combination therapy involves the use of two or more drugs to treat a specific disease or condition.
Combination therapy is used in cardiovascular diseases to achieve better control of blood pressure, reduce the risk of adverse events, and improve patient outcomes. CCBs are often combined with other drugs, such as beta-blockers, diuretics, and ACE inhibitors, to treat various cardiovascular conditions, such as hypertension and angina.
Usage of combination therapies in cardiovascular diseases has been shown to be effective in several clinical trials. For example, the ACCOMPLISH trial found that a combination of the CCB amlodipine and the ACE inhibitor benazepril was more effective in reducing cardiovascular events than either drug alone.
The ALLHAT trial found that a combination of the CCB amlodipine and the ACE inhibitor lisinopril was more effective in reducing the risk of heart failure than the diuretic chlorthalidone.
Surge in usage of combination therapies is ascribed to the need to achieve better control of blood pressure, reduce the risk of adverse events, and improve patient outcomes. As more clinicians and patients become aware of the benefits of combination therapy, the demand for CCBs is expected to rise.
The calcium channel blockers market is expected to experience steady growth as more combination therapies are developed and used to treat cardiovascular diseases.
Adoption of generic drugs is a significant factor driving the calcium channel blockers industry growth. Generic drugs are cheaper alternatives to branded drugs and are bioequivalent to the original drug. The lower cost of generic drugs has made them more accessible to patients, leading to increased adoption. In the case of CCBs, generic drugs are available in various formulations, such as amlodipine, nifedipine, and diltiazem, among others.
Adoption of generic drugs has been driven by cost savings, increased accessibility, and government initiatives. Governments of several countries have implemented policies to promote the use of generic drugs, such as subsidies, pricing regulations, and incentives for physicians to prescribe generic drugs.
Adoption of generic drugs has also been driven by expiration of patents for branded drugs. When the patent for a branded drug expires, other manufacturers can produce generic versions of the drug, leading to increased competition and lower prices. In the case of CCBs, many of the patents for branded drugs have already expired or are set to expire soon, leading to increased availability of generic drugs.
Adoption of generic drugs is expected to drive the global market in the next few years. Increase in availability and adoption of generic CCBs would lead to increased market competition, lower prices, and increased access for patients. As more patients and healthcare providers switch to generic CCBs, demand for these drugs is expected to increase.
In terms of application, the hypertension segment accounted for the largest share of the global calcium channel blockers market in 2022. Hypertension, or high blood pressure, is a widespread medical condition affecting a significant portion of the global population.
According to the World Health Organization (WHO), hypertension is estimated to affect around 1.13 billion people globally. High prevalence of hypertension creates a large patient population in need of treatment, leading to a dominant market segment for calcium channel blockers.
Calcium channel blockers are often recommended as first-line treatment or as part of combination therapy for hypertension. Their efficacy in controlling blood pressure levels makes them a popular choice among healthcare professionals and patients.
Based on distribution channel, the online pharmacies segment dominated the global market in 2022. Convenience, accessibility, cost-effectiveness, regulatory advancements, and the impact of the COVID-19 pandemic collectively contribute to the growth of the segment.
Rise of e-commerce and digital platforms has enabled patients to conveniently order their prescribed medications from the comfort of their homes. The ease of browsing through medication options, comparing prices, and placing orders on online platforms enhances the appeal of purchasing calcium channel blockers online.
Cost is a critical factor in healthcare decisions. Attractive pricing strategy adopted by online pharmacies drives consumers toward purchasing calcium channel blockers online.
North America dominated the global market in 2022. This is ascribed to aging population, advanced healthcare systems, leading pharmaceutical companies, and favorable regulatory environment. These factors have resulted in a large and growing market for CCBs in the region.
North America has a large population of elderly people who are more prone to conditions such as hypertension and angina, which are treated using CCBs. Prevalence of hypertension in the region is expected to increase significantly in the next few years due to changing lifestyles and rise in obesity rates, which is likely to drive demand for these medications.
North America has a well-established healthcare system that is equipped with advanced medical technologies and treatment methods. This has allowed healthcare providers to diagnose and treat conditions more effectively, including prescribing CCBs where necessary.
Favorable regulatory environment in North America encourages innovation and ensures the safety and efficacy of medications. This has attracted pharmaceutical companies to invest in the region, leading to a range of CCB options for healthcare providers and patients.
The calcium channel blockers market in Asia Pacific is expected to grow at a faster pace in the next few years. Large population, increase in healthcare expenditure, rise in prevalence of hypertension, aging population, focus on chronic disease management, and technological advancements contribute to the region's rapid market growth.
This report provides profiles of leading players operating in the global calcium channel blockers market. These include Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Company Inc., Novartis AG, AstraZeneca, Merck & Co. Inc., GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., and Daiichi Sankyo Company, Limited.
These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand their presence and gain global calcium channel blockers market share.
The calcium channel blockers industry research report profiles the top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 14.5 Bn |
|
Forecast (Value) in 2031 |
More than US$ 24.0 Bn |
|
Growth Rate (CAGR) |
5.7% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2022 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 14.5 Bn in 2022
It is projected to reach more than US$ 24.0 Bn by 2031
The CAGR is anticipated to be 5.7% from 2023 to 2031
The dihydropyridine segment accounted for the largest share in 2022
North America is expected to account for leading share during the forecast period.
Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Company, Inc., Novartis AG, AstraZeneca, Merck & Co. Inc., GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., and Daiichi Sankyo Company, Limited. are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Calcium Channel Blockers Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Key product/brand Analysis
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry
6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Phenylalkylamine
6.3.2. Benzothizepine
6.3.3. Dihydropyridine
6.3.3.1. 1st Generation
6.3.3.2. 2nd Generation
6.3.3.3. 3rd Generation
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Hypertension
7.3.2. Angina
7.3.3. Arrhythmia
7.3.4. Hypertrophic Cardiomyopathy
7.3.5. Others (Raynaud's disease, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Calcium Channel Blockers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Phenylalkylamine
11.2.2. Benzothizepine
11.2.3. Dihydropyridine
11.2.3.1. 1st Generation
11.2.3.2. 2nd Generation
11.2.3.3. 3rd Generation
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Hypertension
11.3.2. Angina
11.3.3. Arrhythmia
11.3.4. Hypertrophic Cardiomyopathy
11.3.5. Others (Raynaud's disease, etc.)
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Application
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Calcium Channel Blockers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Phenylalkylamine
12.2.2. Benzothizepine
12.2.3. Dihydropyridine
12.2.3.1. 1st Generation
12.2.3.2. 2nd Generation
12.2.3.3. 3rd Generation
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Hypertension
12.3.2. Angina
12.3.3. Arrhythmia
12.3.4. Hypertrophic Cardiomyopathy
12.3.5. Others (Raynaud's disease, etc.)
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Phenylalkylamine
13.2.2. Benzothizepine
13.2.3. Dihydropyridine
13.2.3.1. 1st Generation
13.2.3.2. 2nd Generation
13.2.3.3. 3rd Generation
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Hypertension
13.3.2. Angina
13.3.3. Arrhythmia
13.3.4. Hypertrophic Cardiomyopathy
13.3.5. Others (Raynaud's disease, etc.)
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Calcium Channel Blockers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Phenylalkylamine
14.2.2. Benzothizepine
14.2.3. Dihydropyridine
14.2.3.1. 1st Generation
14.2.3.2. 2nd Generation
14.2.3.3. 3rd Generation
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Hypertension
14.3.2. Angina
14.3.3. Arrhythmia
14.3.4. Hypertrophic Cardiomyopathy
14.3.5. Others (Raynaud's disease, etc.)
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017-2031
15.2.1. Phenylalkylamine
15.2.2. Benzothizepine
15.2.3. Dihydropyridine
15.2.3.1. 1st Generation
15.2.3.2. 2nd Generation
15.2.3.3. 3rd Generation
15.3. Market Value Forecast, by Application, 2017-2031
15.3.1. Hypertension
15.3.2. Angina
15.3.3. Arrhythmia
15.3.4. Hypertrophic Cardiomyopathy
15.3.5. Others (Raynaud's disease, etc.)
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Application
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Pfizer, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Bausch Health Company, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Novartis AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. AstraZeneca
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co. Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. GSK plc
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Bayer AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Daiichi Sankyo Company, Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
Figure 02. Global Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 03. Global Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 04. Global Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
Figure 05. Global Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
Figure 06. Global Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 07. Global Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 08. Global Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 09. Global Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 10. Global Calcium Channel Blockers Market Value Share Analysis, by Region, 2022 and 2031
Figure 11. Global Calcium Channel Blockers Market Attractiveness Analysis, by Region, 2023-2031
Figure 12. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
Figure 13. North America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 14. North America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 15. North America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
Figure 16. North America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
Figure 17. North America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 18. North America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 19. North America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 20. North America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 21. North America Calcium Channel Blockers Market Value Share Analysis, by Country, 2022 and 2031
Figure 22. North America Calcium Channel Blockers Market Attractiveness Analysis, by Country, 2023-2031
Figure 23. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
Figure 24. Europe Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 25. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 26. Europe Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
Figure 27. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
Figure 28. Europe Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 29. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 30. Europe Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 31. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 32. Europe Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
Figure 35. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 36. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 37. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
Figure 38. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
Figure 39. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 40. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 41. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 43. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 44. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 45. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
Figure 46. Latin America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 47. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 48. Latin America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
Figure 49. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
Figure 50. Latin America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 51. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 52. Latin America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 53. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 54. Latin America Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 55. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
Figure 57. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 58. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 59. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
Figure 60. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
Figure 61. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 62. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 63. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 64. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 65. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 66. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 67. Global Calcium Channel Blockers Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Calcium Channel Blockers Market
